Press Release Hub logo
  • Submit a Release
  • Home
  • All
  • ESG
  • Health
  • Technology
  • Finance
  • Contributors

BetaGlue Therapeutics Expands its Clinical Trial in Italy after obtaining from the Italian Ministry of Health Approval to conduct its clinical study in Unresectable Locally Advanced Pancreatic Cancer (uLA-PDAC)

Contributed by: GlobeNewswire

Tags

Pancreas

More Like This

BetaGlue Therapeutics Receives Belgium Ministry of Health Approval for YntraDose Clinical Trial in Unresectable Locally Advanced Pancreatic Cancer (uLA-PDAC)

MHRA Approves BetaGlue Therapeutics’ Clinical Trial Application for YntraDose™ in unresectable Locally Advanced Pancreatic Cancer (uLA-PDAC)

BetaGlue Therapeutics Announces the Appointment of Alexis Peyroles as New Chief Executive Officer

PR Newswire associated0

GammaPod revolutionizes breast cancer treatment: Italy introduces high-dose stereotactic radiotherapy in a single session to Europe

PR Newswire associated0

A Global Milestone in Innovative Pancreatic Cancer Therapy

Business Wire logo

Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma

Business Wire logo

Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026

How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options

Pages

  • Home
  • All
  • ESG
  • Health
  • Technology
  • Finance
  • Contributors

Press Release Hub

  • Our Services
  • Submit a Release

Websites

  • PA Media Group
  • PA Mediapoint
  • Distribution Packages

© PA Media Group. 2026

Terms of Use

Privacy Policy

Contact Us